AU2014275094C1 - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor - Google Patents

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor Download PDF

Info

Publication number
AU2014275094C1
AU2014275094C1 AU2014275094A AU2014275094A AU2014275094C1 AU 2014275094 C1 AU2014275094 C1 AU 2014275094C1 AU 2014275094 A AU2014275094 A AU 2014275094A AU 2014275094 A AU2014275094 A AU 2014275094A AU 2014275094 C1 AU2014275094 C1 AU 2014275094C1
Authority
AU
Australia
Prior art keywords
antibody
subject
antigen
medicament
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014275094A
Other languages
English (en)
Other versions
AU2014275094A1 (en
AU2014275094B2 (en
Inventor
Namita GANDHI
Neil Graham
Andrew J. Murphy
Jamie M. Orengo
Neil Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2014275094A1 publication Critical patent/AU2014275094A1/en
Application granted granted Critical
Publication of AU2014275094B2 publication Critical patent/AU2014275094B2/en
Priority to AU2019204577A priority Critical patent/AU2019204577B2/en
Publication of AU2014275094C1 publication Critical patent/AU2014275094C1/en
Priority to AU2021229250A priority patent/AU2021229250B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
AU2014275094A 2013-06-04 2014-06-03 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor Active AU2014275094C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019204577A AU2019204577B2 (en) 2013-06-04 2019-06-27 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
AU2021229250A AU2021229250B2 (en) 2013-06-04 2021-09-10 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361830919P 2013-06-04 2013-06-04
US61/830,919 2013-06-04
PCT/US2014/040695 WO2014197470A1 (en) 2013-06-04 2014-06-03 Mehods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019204577A Division AU2019204577B2 (en) 2013-06-04 2019-06-27 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

Publications (3)

Publication Number Publication Date
AU2014275094A1 AU2014275094A1 (en) 2015-12-17
AU2014275094B2 AU2014275094B2 (en) 2019-03-28
AU2014275094C1 true AU2014275094C1 (en) 2019-10-10

Family

ID=51023185

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014275094A Active AU2014275094C1 (en) 2013-06-04 2014-06-03 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor
AU2019204577A Active AU2019204577B2 (en) 2013-06-04 2019-06-27 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
AU2021229250A Active AU2021229250B2 (en) 2013-06-04 2021-09-10 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019204577A Active AU2019204577B2 (en) 2013-06-04 2019-06-27 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
AU2021229250A Active AU2021229250B2 (en) 2013-06-04 2021-09-10 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4r inhibitor

Country Status (25)

Country Link
US (5) US10392439B2 (enExample)
EP (2) EP3004166B1 (enExample)
JP (6) JP6499167B2 (enExample)
KR (3) KR102580468B1 (enExample)
CN (3) CN117982639A (enExample)
AU (3) AU2014275094C1 (enExample)
CA (1) CA2914203C (enExample)
CY (1) CY1124095T1 (enExample)
DK (1) DK3004166T3 (enExample)
ES (1) ES2767080T3 (enExample)
HR (1) HRP20200185T1 (enExample)
HU (1) HUE048655T2 (enExample)
IL (3) IL312710A (enExample)
LT (1) LT3004166T (enExample)
MX (2) MX384112B (enExample)
NZ (1) NZ630183A (enExample)
PL (1) PL3004166T3 (enExample)
PT (1) PT3004166T (enExample)
RS (1) RS59883B1 (enExample)
RU (1) RU2679920C2 (enExample)
SG (3) SG10201913835XA (enExample)
SI (1) SI3004166T1 (enExample)
TW (3) TWI633891B (enExample)
WO (1) WO2014197470A1 (enExample)
ZA (1) ZA201508174B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
HUE064945T2 (hu) 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
KR20160024916A (ko) 2013-06-21 2016-03-07 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
WO2016156588A1 (en) * 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
JP7008020B2 (ja) * 2015-12-18 2022-01-25 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
RU2753869C2 (ru) 2016-02-19 2021-08-24 Ридженерон Фармасьютикалз, Инк. Способы повышения эффективности вакцины путем введения антагониста il-4r
KR102845317B1 (ko) * 2016-03-01 2025-08-13 코어셉트 쎄라퓨틱스 인코포레이티드 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
EP4442323A3 (en) * 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
EP3513196A1 (en) * 2016-09-16 2019-07-24 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
ES3032778T3 (en) 2016-10-25 2025-07-24 Regeneron Pharma Methods for chromatography data analysis
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
MY203415A (en) 2017-09-19 2024-06-27 Regeneron Pharma Methods of reducing particle formation and compositions formed thereby
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CA3084155A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
WO2019229525A2 (en) * 2018-04-25 2019-12-05 Kiniksa Pharmaceuticals, Ltd. TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
MX2021000239A (es) * 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
US20220049002A1 (en) * 2018-09-14 2022-02-17 Kindred Biosciences, Inc. Anti-IL4 Receptor Antibodies for Veterinary Use
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111518211B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
SG11202107007VA (en) * 2018-12-27 2021-07-29 Akeso Biopharma Inc Antibody against human il-4ra and use thereof
RU2700788C1 (ru) * 2019-01-17 2019-09-23 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ оценки эффективности проведения аллерген-специфической иммунотерапии при аллергическом рините
MX2021011141A (es) 2019-03-21 2022-01-19 Regeneron Pharma Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
EP4010001A1 (en) * 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
WO2021102186A1 (en) * 2019-11-20 2021-05-27 Aimmune Therapeutics, Inc. Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drug
US11723974B2 (en) 2019-12-09 2023-08-15 Sanofi-Aventis Biotechnology Methods for treating digitally identified IL-4/IL-13-related disorders by administering an anti-IL4R-alpha antibody
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN116348605A (zh) * 2020-07-17 2023-06-27 Gi 医诺微新 包含IgE Fc受体α亚基胞外结构域和抗IL-4R抗体的融合蛋白及其应用
AU2022206434A1 (en) * 2021-01-08 2023-08-24 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
WO2023009437A1 (en) * 2021-07-26 2023-02-02 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
CN115960236B (zh) * 2023-01-05 2024-08-06 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039461A1 (en) * 2012-09-07 2014-03-13 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
BR9205967A (pt) 1991-05-03 1994-07-26 Seragen Inc Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
WO2000016804A1 (en) 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
CA2446108A1 (en) 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
EP1461300B1 (en) 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
MXPA04009418A (es) 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
SI2407485T1 (sl) 2003-02-01 2016-09-30 Tanox, Inc. Visoko afinitetna anti-humana protitelesa IgE
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
CA2554596A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
HRP20140661T1 (hr) 2007-03-22 2014-10-10 Genentech, Inc. Apoptotiäśka protutijela anti-ige koja vežu ige spojen s membranom
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20110301046A1 (en) 2008-12-01 2011-12-08 Children's Hospital Medical Center Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
KR101867279B1 (ko) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
EP2763683A1 (en) 2011-10-06 2014-08-13 N.V. Nutricia Treatment of eosinophilic esophagitis
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
HUE064945T2 (hu) 2012-08-21 2024-04-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
KR20160024916A (ko) 2013-06-21 2016-03-07 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
EP3218412A1 (en) * 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
RU2753869C2 (ru) 2016-02-19 2021-08-24 Ридженерон Фармасьютикалз, Инк. Способы повышения эффективности вакцины путем введения антагониста il-4r
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP4442323A3 (en) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
AU2017332732B2 (en) 2016-09-22 2024-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
MX2021011141A (es) 2019-03-21 2022-01-19 Regeneron Pharma Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4010001A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
US11723974B2 (en) 2019-12-09 2023-08-15 Sanofi-Aventis Biotechnology Methods for treating digitally identified IL-4/IL-13-related disorders by administering an anti-IL4R-alpha antibody
US20250154267A2 (en) 2020-05-22 2025-05-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039461A1 (en) * 2012-09-07 2014-03-13 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRUNEWALD, S.M. et al., The Journal of Immunology. 1998, Vol. 160, pages 4004-4009 *
Regeneron Pharmaceuticals, <URL: http://files.shareholder.com/downloads/REGN/2689212012x0x640531/794a7e54-6904-416b-ba38-a4ccc1726852/REGN%20News%202013%203%202%20General%20Releases.pdf%3E>, published 2 March 2013 *
WENZEL, S. et al., ‘Dupilumab in Persistent Asthma with Elevated Eosinophil Levels’, The New England Journal of Medicine. Published online 21 May 2013, Vol. 368, No. 26, pages 2455-2466 *

Also Published As

Publication number Publication date
TW201906630A (zh) 2019-02-16
AU2019204577A1 (en) 2019-07-18
DK3004166T3 (da) 2020-01-06
CN118001391A (zh) 2024-05-10
AU2021229250B2 (en) 2024-11-14
JP2025011257A (ja) 2025-01-23
HK1216898A1 (en) 2016-12-09
IL273678A (en) 2020-05-31
TWI755763B (zh) 2022-02-21
EP3004166B1 (en) 2019-11-20
US20180094070A1 (en) 2018-04-05
TWI697334B (zh) 2020-07-01
IL312710A (en) 2024-07-01
RS59883B1 (sr) 2020-03-31
ES2767080T3 (es) 2020-06-16
AU2021229250A1 (en) 2021-10-07
US10392439B2 (en) 2019-08-27
RU2015156628A (ru) 2017-07-14
US20180094069A1 (en) 2018-04-05
MX2015016473A (es) 2016-03-03
JP2019112440A (ja) 2019-07-11
JP6499167B2 (ja) 2019-04-10
IL273678B1 (en) 2024-06-01
KR102492826B1 (ko) 2023-01-30
AU2019204577B2 (en) 2021-06-24
MX2021002173A (es) 2021-04-28
TWI633891B (zh) 2018-09-01
US11485788B2 (en) 2022-11-01
PL3004166T3 (pl) 2020-06-01
CN117982639A (zh) 2024-05-07
IL242456B (en) 2020-04-30
US10669341B2 (en) 2020-06-02
JP2020193218A (ja) 2020-12-03
JP7061163B2 (ja) 2022-04-27
JP7575526B2 (ja) 2024-10-29
US20200299393A1 (en) 2020-09-24
EP3004166A1 (en) 2016-04-13
CA2914203C (en) 2024-04-16
LT3004166T (lt) 2019-12-27
CA2914203A1 (en) 2014-12-11
TW201519905A (zh) 2015-06-01
CN105377894A (zh) 2016-03-02
SI3004166T1 (sl) 2020-02-28
IL273678B2 (en) 2024-10-01
AU2014275094A1 (en) 2015-12-17
ZA201508174B (en) 2017-09-27
SG10201709670XA (en) 2018-01-30
MX384112B (es) 2025-03-14
HRP20200185T1 (hr) 2020-05-01
SG10201913835XA (en) 2020-03-30
KR102355114B1 (ko) 2022-01-27
US20140356372A1 (en) 2014-12-04
JP2016521713A (ja) 2016-07-25
JP6754857B2 (ja) 2020-09-16
SG11201509044QA (en) 2015-12-30
CY1124095T1 (el) 2022-03-24
HUE048655T2 (hu) 2020-08-28
TW202038999A (zh) 2020-11-01
RU2679920C2 (ru) 2019-02-14
KR20160014626A (ko) 2016-02-11
JP7284313B2 (ja) 2023-05-30
PT3004166T (pt) 2020-01-14
KR20230017923A (ko) 2023-02-06
AU2014275094B2 (en) 2019-03-28
EP3617233A1 (en) 2020-03-04
RU2019103601A (ru) 2019-03-12
US10676530B2 (en) 2020-06-09
NZ630183A (en) 2018-10-26
KR102580468B1 (ko) 2023-09-21
RU2015156628A3 (enExample) 2018-05-30
JP2023103389A (ja) 2023-07-26
US20230159647A1 (en) 2023-05-25
JP2022101613A (ja) 2022-07-06
WO2014197470A1 (en) 2014-12-11
KR20220011810A (ko) 2022-01-28

Similar Documents

Publication Publication Date Title
US20230159647A1 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
HK40022146A (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
RU2789047C2 (ru) Способы лечения аллергии и повышения эффективности аллерген- специфической иммунотерапии путем введения ингибитора ил-4р
HK1216898B (en) Methods for enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 JUN 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 27 JUN 2019

FGA Letters patent sealed or granted (standard patent)